SABCS Reaction
December 9, 2022

SABCS Reactions - P2RIGHT Choice

SABCS Reaction
December 11, 2022

SABCS Reactions - P2RIGHT Choice

Author

Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy.

Abstract #GS1-10: Prof. Yen-Shen Lu  presented primary results of the P2RIGHT Choice trial, assessing ribociclib +endocrine therapy (ET) vs physician’s choice combination chemotherapy in 222 premenopausal patients withaggressive HR+/HER2− advanced breast cancer.

Results:

  • Ribociclib-ET achieved a 46% reduction in the risk of disease progression or death vs chemo
  • Ribociclib-ET showed improvement in PFS compared with chemotherapy (24.0 months vs 12.3 months for chemo); OS data immature
  • Median time to treatment failure was significantly longer with ribociclib-ET (18.6 months vs. 8.5 months for chemo)
  • ORR was 65.2% vs 60.0% with ribociclib-ET vs chemo. Clinical benefit rate was 80.4% vs 72.7%, respectively
  • TRAEs occurred in 1.8% in the ribociclib-ET vs 8.0% in the chemo arm; Grade 3/4 AEs were in 0.9% vs 7.0%, respectively. Discontinuation was 7.1% in the ribociclib-ET arm vs 23.0% for chemo
  • Thought leader reactions were positive, with several oncologists advocating changing guidelines for patients with aggressive HR+ mBC to make CKD4/6i + ET a first line treatment instead of chemotherapy.

    Ribociclib’s significant advantages in tolerability garnered interest as well.

    One thought leader feared access delays for ribociclib and other CDK4/6 inhibitors, which would hinder uptake.

    Summary: Thought leaders believe that the efficacy and tolerability data presented for ribociclib plus endocrine therapy shows that it has the potential to replace chemotherapy and become the recommended first line treatment for HR+, HER2-, aggressive breast cancer.

    Synthesis powered by Opus Strategy

    Download attached file
    Not rated
    Allison Betof Warner, MD, PhD (she/her) 4
    3743
    Manhattan, NY
    November 10, 2022

    79% had reduction in disease. ORR 31%. Many responses deepen over time.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 3
    3743
    Manhattan, NY
    November 10, 2022

    Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

    Positive
    Alex Shoushtari, MD
    2253
    New York, USA
    November 10, 2022

    Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 2
    3743
    Manhattan, NY
    November 10, 2022

    Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

    Positive
    Hussein Tawbi, MD, PhD
    1685
    Houston, TX
    November 10, 2022

    Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

    Positive
    Allison Betof Warner, MD, PhD (she/her) 1
    3744
    Manhattan, NY
    November 10, 2022

    Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

    Not Rated
    Sumanta K. Pal, MD, FASCO
    15083 Followers
    Los Angeles, CA
    November 8, 2022

    Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

    not rated
    Shilpa Gupta
    5095 Followers
    Cleveland, OH
    November 8, 2022
    Not Rated
    Tian Zhang, MD, MHS
    6463 Followers
    Dallas, TX
    November 8, 2022

    CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

    Not Rated
    Moshe Ornstein MD
    1930 Followers
    Cleveland, OH
    November 8, 2022

    Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

    Not Rated
    Shuchi Gulati MD
    12476 Followers
    Seattle, WA
    November 8, 2022

    Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

    Not Rated
    Petros Grivas
    12476 Followers
    Seattle, WA
    November 8, 2022

    Subscribe to our newsletter

    Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
    Thank you! Your submission has been received!
    Oops! Something went wrong while submitting the form.